Poly Medicure: PAT Growth Lags at 3.6% on Margin Pressure
POLYMED Poly Medicure (NSE : POLYMED) manufactures finished medical devices across infusion therapy, renal care and cardiology. Its product range covers IV cannulas, needle-free connectors, dialysis machines, drug-eluting stents and cardiovascular catheters. It operates 15 plants across five countries with annual production capacity of 1.9 billion units. What happened: In Q2 FY27, revenue grew 30.8% year on year to Rs 580.5 crore. EBITDA rose 20.1% to Rs 139.1 crore, with margin at 24%, down 210 basis points. PAT grew only 3.6% to Rs 95.1 crore. International markets contributed 71% of H1 FY27 revenue. The company added 30 international customers in H1 and commenced first dispatches from its Brazilian subsidiary in October. Why it matters: Revenue is growing but earnings are not keeping pace. Acquisitions, overseas establishment costs and higher freight expenses are compressing margins. The company has filed an anti-dumping case against Chinese dialysis equipment imports. It is targeting a doubling of revenue by FY30, with FY27 capex guidance of Rs 200 to 225 crore. What I am watching: Whether margin recovery follows revenue expansion. The cash conversion cycle edged up to 136 days from 135, and inventory days rose to 73 from 70. The cardiology portfolio, including drug-eluting stents, is at an early clinical stage and needs to demonstrate repeat commercial demand beyond initial launches. My stance: Poly Medicure trades at approximately 54 times earnings and has declined 12% over the past year. ROCE is 12.5% and ROE is 9.8%. The revenue trajectory is strong, but the valuation requires earnings to recover alongside expansion. That recovery is not yet visible in the numbers. I do not hold a position in Poly Medicure at the time of writing. This is not investment advice.



















